Exkivity
Janssen Seeking Rybrevant-Chemo Approval in Europe for First-Line EGFR-Mutated NSCLC
The drugmaker has filed an application with the European Medicines Agency seeking approval for the regimen in NSCLC with EGFR exon 20 insertion mutations.
The drugmaker has filed an application with the European Medicines Agency seeking approval for the regimen in NSCLC with EGFR exon 20 insertion mutations.